HIV/AIDS

HIV/AIDS

HIV and ID Observations Blog

Post-Exposure Prophylaxis for HCV Can’t Be Cost-Effective — But We Might End Up Recommending It Anyway Free

Is post-exposure prophylaxis for hepatitis C virus a no-brainer? Dr. Paul Sax asks this question in HIV and ID Observations.

Drug Watch

Dolutegravir

The FDA has approved the integrase inhibitor dolutegravir for treatment of HIV infection, in combination with other antiretrovirals.